Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serine peptidase inhibitor Kazal type 9 (SPINK9)
- Target
- SPINK9
- Molecular classification
- Enzyme inhibitor, Serine protease inhibitor, Kazal-type inhibitor
01
Overview
Serine peptidase inhibitor Kazal type 9 (SPINK9) is a cationic, Kazal-type serine protease inhibitor that is highly specific for kallikrein-related peptidase 5 (KLK5), a protease responsible for initiating skin desquamation. SPINK9 is predominantly expressed in the palmo-plantar epidermis, where it is thought to regulate skin differentiation and barrier function by inhibiting KLK5-mediated proteolysis. Additionally, SPINK9 can promote keratinocyte migration through a metalloprotease and EGFR-dependent mechanism. Pathological alterations in SPINK9 have been associated with certain skin diseases such as Norwegian scabies and pompholyx[1][2][4][5]. No drugs are reported to target SPINK9 directly.
- Other names
- Serine protease inhibitor Kazal-type 9LEKTI2Lymphoepithelial Kazal-type-related inhibitor 2
02
Mechanism of action
No drugs known to target this molecule; physiological action is inhibition of KLK5
03
Biological functions
Inhibition of serine-type endopeptidases (specifically KLK5)Regulation of skin desquamationPromotion of keratinocyte migration via metalloprotease/EGFR-dependent pathway
04
Disease associations
Skin disease (e.g., Norwegian scabies, pompholyx)
Beyond the preview
Go deeper on Serine peptidase inhibitor Kazal type 9 (SPINK9).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Serine peptidase inhibitor Kazal type 9 (SPINK9).